Rosaria Chilà

FIRC Institute of Molecular Oncology — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index974citations60works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(23), Lymphoma Diagnosis and Treatment(13), Cancer-related Molecular Pathways(8), Genetic factors in colorectal cancer(8), Cancer therapeutics and mechanisms(8)

Publications60 total

Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models
Cancer Cell·2025· 10 citedOpen Access
Abstract 6169: Immunogenic cell death mediates the anticancer efficacy of high dose vitamin C
Cancer Research·2025
Abstract 6155: The combination of cisplatin and temozolomide triggers immune surveillance through antigen-dependent and independent mechanisms
Cancer Research·2025
26P Response in patient-derived models recapitulates circulating tumor DNA clearance of matched colon cancer patients after adjuvant treatment in the PEGASUS trial
Annals of Oncology·2024Open Access
Abstract 5284: Immune surveillance of chemotherapy-induced mutant subclones in CRC
Cancer Research·2024
Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer
Genome Medicine·2024· 15 citedOpen Access
2235P Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Annals of Oncology·2023
18P Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Annals of Oncology·2023Open Access
Abstract 6402: The effects of cytotoxic chemotherapy on colorectal cancer immunogenicity
Cancer Research·2023
Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplememntary Table 3 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Data from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
Data from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Giovanna Damia(33), Monica Lupi(20), Laura Carrassa(19), Valentina Restelli(16), Federica Di Nicolantonio(15), Alberto Bardelli(15), Simona Lamba(14), Francesco Bertoni(14), Eugenio Gaudio(11), Chiara Tarantelli(11), Micaela Vagni(11), Filippo Spriano(10), Giovanni Germano(9), Federica Guffanti(9), Federica Pisati(9), Gianluca Mauri(9), Silvia Marsoni(9), Annalisa Lorenzato(8), Vito Amodio(8), Francesca Ricci(8)